Literature DB >> 26383137

MYC: Splicing up your survival.

Gemma K Alderton.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26383137     DOI： 10.1038/nrc4013

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer.

Authors:  Tiffany Y-T Hsu; Lukas M Simon; Nicholas J Neill; Richard Marcotte; Azin Sayad; Christopher S Bland; Gloria V Echeverria; Tingting Sun; Sarah J Kurley; Siddhartha Tyagi; Kristen L Karlin; Rocio Dominguez-Vidaña; Jessica D Hartman; Alexander Renwick; Kathleen Scorsone; Ronald J Bernardi; Samuel O Skinner; Antrix Jain; Mayra Orellana; Chandraiah Lagisetti; Ido Golding; Sung Y Jung; Joel R Neilson; Xiang H-F Zhang; Thomas A Cooper; Thomas R Webb; Benjamin G Neel; Chad A Shaw; Thomas F Westbrook
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962
  1 in total
  2 in total

1.  Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models.

Authors:  Shivendra Singh; Waise Quarni; Maria Goralski; Shibiao Wan; Hongjian Jin; Lee-Ann Van de Velde; Jie Fang; Qiong Wu; Ahmed Abu-Zaid; Tingting Wang; Ravi Singh; David Craft; Yiping Fan; Thomas Confer; Melissa Johnson; Walter J Akers; Ruoning Wang; Peter J Murray; Paul G Thomas; Deepak Nijhawan; Andrew M Davidoff; Jun Yang
Journal:  Sci Adv       Date:  2021-11-17       Impact factor: 14.136

2.  FIR haplodeficiency promotes splicing to pyruvate kinase M2 in mice thymic lymphoma tissues revealed by six-plex tandem mass tag quantitative proteomic analysis.

Authors:  Asako Kimura; Kouichi Kitamura; Guzhanuer Ailiken; Mamoru Satoh; Toshinari Minamoto; Nobuko Tanaka; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2017-07-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.